Reprogramming induced by isoliquiritigenin diminishes melanoma cachexia through mTORC2-AKT-GSK3β signaling

Oncotarget

Volumn 8, Issue 21, 2017, Pages 34565-34575

  Chen, Xiao Yu ^a   Li, De Fang ^b   Han, Ji Chun ^b   Wang, Bo ^c   Dong, Zheng Ping ^b   Yu, Li Na ^b   Pan, Zhao Hai ^b   Qu, Chuan Jun ^b   Chen, Ying ^b   Sun, Shi Guo ^a   Zheng, Qiu Sheng ^b  

^a NORTHWEST A F UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

^c SHIHEZI UNIVERSITY   (China)

Author keywords

Cachexia; Isoliquiritigenin; Melanoma; MTORC2 AKT GSK3 signaling; Reprogramming

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3BETA; ISOLIQUIRITIGENIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MONOPHENOL MONOOXYGENASE; PROTEIN KINASE B; 5 [2 (2,6 DIMETHYLMORPHOLINO) 4 MORPHOLINOPYRIDO[2,3 D]PYRIMIDIN 7 YL] 2 METHOXYBENZENEMETHANOL; CHALCONE DERIVATIVE; ENZYME INHIBITOR; GLUCOSE; GSK3B PROTEIN, HUMAN; LACTIC ACID; MORPHOLINE DERIVATIVE; OXYGEN; PYRIMIDINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CACHEXIA; CELL CYCLE ARREST; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; GLUCOSE TRANSPORT; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOGENESIS; MELANOMA; NUCLEAR REPROGRAMMING; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPECTROPHOTOMETRY; CELL CYCLE; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CHALCONES; DRUG SYNERGISM; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3 BETA; HUMANS; LACTIC ACID; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 2; MELANOMA; MORPHOLINES; OXYGEN; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 85019846259     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16655     Document Type: Article

References (44)

1. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. Cell. 2008; 132:567-82. doi: 10.1016/j.cell.2008.01.015
2. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, Bernstein BE, Jaenisch R. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007; 448:318-24
3. Zhang X, Cruz FD, Terry M, Remotti F, Matushansky I. Terminal differentiation and loss of tumorigenicity of human cancers via pluripotency-based reprogramming. Oncogene. 2013; 32:2249-60, 2260.e1-21. doi: 10.1038/onc.2012.237
4. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med. 1998; 4:1046-52
5. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma innon-small cell lung cancer. Cancer Res. 2000; 60:1129-38
6. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell. 1998; 1:465-70
7. Hsu PP, Sabatini DM. Cancer cell metabolism: Warburg and beyond. Cell. 2008; 134:703-7. doi: 10.1016/j. cell.2008.08.021
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-74. doi: 10.1016/j. cell.2011.02.013
9. Shukla SK, Gebregiworgis T, Purohit V, Chaika NV, Gunda V, Radhakrishnan P, Mehla K, Pipinos II, Powers R, Yu F, Singh PK. Metabolic reprogramming induced by ketone bodies diminishes pancreatic cancer cachexia. Cancer Metab. 2014; 2:18. doi: 10.1186/2049-3002-2-18
10. Liu L, Gong L, Zhang Y, Li N. Glycolysis in Panc-1 human pancreatic cancer cells is inhibited by everolimus. Exp Ther Med. 2013; 5:338-342
11. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005; 17:596-603
12. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009; 7:e38. doi: 10.1371/journal.pbio.1000038
13. Laplante M, Sabatini DM. mTOR Signaling. Cold Spring Harb Perspect Biol. 2012; 4. pii: a011593. doi: 10.1101/cshperspect.a011593
14. Zeng Z, Sarbassov dos D, Samudio IJ, Yee KW, Munsell MF, Ellen Jackson C, Giles FJ, Sabatini DM, Andreeff M, Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007; 109:3509-12
15. Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med. 2014; 11:255-63. doi: 10.7497/j.issn.2095-3941. 2014.04.004
16. Zeng H, Cohen S, Guy C, Shrestha S, Neale G, Brown SA, Cloer C, Kishton RJ, Gao X, Youngblood B, Do M, Li MO, Locasale JW, et al. mTORC1 and mTORC2 Kinase Signaling and Glucose Metabolism Drive Follicular Helper T Cell Differentiation. Immunity. 2016; 45:540-54. doi: 10.1016/j. immuni.2016.08.017
17. Esen E, Chen J, Karner CM, Okunade AL, Patterson BW, Long F. WNT-LRP5 signaling induces Warburg effect through mTORC2 activation during osteoblast differentiation. Cell Metab. 2013; 17:745-55. doi: 10.1016/j.cmet.2013.03.017
18. Shu L, Houghton PJ. The mTORC2 complex regulates terminal differentiation of C2C12 myoblasts. Mol Cell Biol. 2009; 29:4691-700. doi: 10.1128/MCB.00764-09
19. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013; 18:726-39. doi: 10.1016/j.cmet.2013.09.013
20. Roulin D, Cerantola Y, Dormond-Meuwly A, Demartines N, Dormond O. Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo. Mol Cancer. 2010; 9:57. doi: 10.1186/1476-4598-9-57
21. Figlin RA, Kaufmann I, Brechbiel J. Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistanceto VEGFR and mTORC1 inhibitors. Int J Cancer. 2013; 133:788-96. doi: 10.1002/ijc.28023
22. Ma J, Fu NY, Pang DB, Wu WY, Xu AL. Apoptosis induced by isoliquiritigenin in human gastric cancer MGC-803 cells. Planta Med. 2001; 67:754-7
23. Baba M, Asano R, Takigami I, Takahashi T, Ohmura M, Okada Y, Sugimoto H, Arika T, Nishino H, Okuyama T. Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethaneinduced murine colon aberrant crypt focus formation and carcinogenesis. Biol Pharm Bull. 2002; 25:247-50
24. Rafi MM, Vastano BC, Zhu N, Ho CT, Ghai G, Rosen RT, Gallo MA, DiPaola RS. Novel polyphenol molecule isolated from licorice root (Glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and Bcl-2 phosphorylation in tumor cell lines. J Agric Food Chem. 2002; 50:677-84
25. Li D, Wang Z, Chen H, Wang J, Zheng Q, Shang J, Li J. Isoliquiritigenin induces monocytic differentiation of HL-60 cells. Free Radic Biol Med. 2009; 46:731-6. doi: 10.1016/j. freeradbiomed. 2008.11.011
26. Chen X, Zhang B, Yuan X, Yang F, Liu J, Zhao H, Liu L, Wang Y, Wang Z, Zheng Q. Isoliquiritigenininduced differentiation in mouse melanoma B16F0 cell line. Oxid Med Cell Longev. 2012; 2012:534934. doi: 10.1155/2012/534934
27. Chen X, Yang M, Hao W, Han J, Ma J, Wang C, Sun S, Zheng Q. Differentiation-inducing and anti-proliferative activities of isoliquiritigenin and all-trans-retinoic acid on B16F0 melanoma cells: Mechanisms profiling by RNA-seq. Gene. 2016; 592:86-98. doi: 10.1016/j.gene.2016.07.052
28. Wang Y, Ma J, Yan X, Chen X, Si L, Liu Y, Han J, Hao W, Zheng Q. Isoliquiritigenin Inhibits Proliferation and Induces Apoptosis via Alleviating Hypoxia and Reducing Glycolysis inMouse Melanoma B16F10 Cells. Recent Pat Anticancer Drug Discov. 2016; 11:215-27
29. Shim H, Chun YS, Lewis BC, Dang CV. A unique glucosedependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA. 1998; 95:1511-6
30. Warrell RP Jr, Maslak P, Eardley A, Heller G, Miller WH Jr, Frankel SR. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia. 1994; 8:929-33
31. Ghanem G, Fabrice J. Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma. Mol Oncol. 2011; 5:150-5. doi: 10.1016/j.molonc.2011.01.006
32. Wellbrock C, Rana S, Paterson H, Pickersgill H, Brummelkamp T, Marais R. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS One. 2008; 3:e2734. doi: 10.1371/journal. pone.0002734
33. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012; 21:297-308. doi: 10.1016/j.ccr.2012.02.014
34. de Souza AC, Justo GZ, de Araújo DR, Cavagis AD. Defining the molecular basis of tumor metabolism: a continuing challenge since Warburgs discovery. Cell Physiol Biochem. 2011; 28:771-92
35. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45:1127-33. doi: 10.1038/ng.2762
36. Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev. 2013; 23:53-62. doi: 10.1016/j.gde.2012.12.005
37. Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD. A growing role for mTOR in promoting anabolic metabolism. Biochem Soc Trans. 2013; 41:906-12. doi: 10.1042/BST20130041
38. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov. 2011; 1:524-38. doi: 10.1158/2159-8290.CD-11-0124
39. Shimada K, Filipuzzi I, Stahl M, Helliwell SB, Studer C, Hoepfner D, Seeber A, Loewith R, Movva NR, Gasser SM. TORC2 signaling pathway guarantees genome stability in the face of DNA strand breaks. Mol Cell. 2013; 51:829-39. doi: 10.1016/j.molcel.2013.08.019
40. Read RD, Cavenee WK, Furnari FB, Thomas JB. A drosophila model for EGFR-Ras and PI3K-dependent human glioma. PLoS Genet. 2009; 5:e1000374. doi: 10.1371/journal. pgen.1000374
41. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide3-kinase/AKT pathway. Proc Natl Acad Sci USA. 1999; 96:4240-5
42. Shakoori A, Ougolkov A, Yu ZW, Zhang B, Modarressi MH, Billadeau DD, Mai M, Takahashi Y, Minamoto T. Deregulated GSK3beta activity in colorectal cancer: its association with tumor cell survival and proliferation. Biochem Biophys Res Commun. 2005; 334:1365-73
43. Liu Y, Peterson DA, Kimura H, Schubert D. Mechanism of cellular 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem. 1997; 69:581-93
44. Siemens H, Jackstadt R, Kaller M, Hermeking H. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness. Oncotarget. 2013; 4:1399-415. doi: 10.18632/oncotarget.1202